GE building Ireland campus with four of its prefab plants

Having won a couple of deals to build its prefabricated manufacturing facilities in Asia, GE will now invest €150 million to build out an entire campus in Ireland that will showcase its off-the-shelf technology.

The biopharmaceutical manufacturing campus will include four of GE’s KUBio plants and is expected to employ about 500 if it gets fully occupied. About 100 of those jobs would be GE employees handling centralized and shared services for the companies in the four KUBios. It is being built on a site owned by Ireland’s Industrial Development Agency (IDA) at Loughbeg, Ringaskiddy, Co. Cork, the company said today in an announcement. Construction is set to begin by mid-2017, it said.

GE has also agreed to partner with Ireland National Institute for Bioprocessing Research and Training to create a training facility in Dublin that is expected train up to 1,500 biologics plant workers a year.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

While the company does not yet have takers for the four plants, a GE spokesperson said in an email today that GE is having “in-depth discussions with a number of companies who are very interested in the concept of BioPark and KUBio in Europe.”

GE has a production facility in Germany to build the prefab parts of the plants, which can then be shipped and quickly erected. It has likened their assembly to working with LEGO blocks and claims they can cut as much as 45% off the cost of building a new plant. It erected one in Wuhan, China, last year for JHL Biotech, a company founded by U.S. biotech veterans working on biosimilars, that took 11 days to assemble.

In June, Pfizer announced it would spend $350 million to have GE build one of the modular biologics plants in Hangzhou, China, which Pfizer will use to make biosimilars for the Chinese market and for export. It said it expected the plant to be operational in about 18 months, instead of three years.

- here’s the release

Related Articles:
Pfizer building modular biologics plant in China
First prefab biologics plant goes up in China, in 11 days

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.